Search the Newsreel

Revvity (RVTY) Stock Looks Reasonable On Cash Flow Yet Rich On Earnings

Revvity (RVTY) stock has seen a 34.1% decline over the past five years. While a Discounted Cash Flow (DCF) model suggests the shares are undervalued by 23.0% at $153 per share, earnings-based multiples indicate the stock is expensive, trading at a P/E of 55.4x …

Revvity Launches SuperFlex Prenatal Screening System for Smaller Labs

Revvity, Inc. RVTY recently announced the launch of the SuperFlex prenatal screening system, a compact, CE-IVDR-certified automated immunoassay instrument designed to expand access to prenatal and preeclampsia testing. Purpose-built for small to mid-sized laboratories and clinics, the platform is intended to bring reliable, rapid …

Revvity Inc. (NYSE:RVTY) Given Average Recommendation of "Hold" by Analysts

Revvity Inc. (NYSE:RVTY) has received an average "Hold" recommendation from analysts, with 12 out of 15 rating it a hold and three a buy. Despite exceeding quarterly earnings and revenue expectations, the company's revenue declined 1.3% year over year, and the average 12-month price …

Revvity Inc. stock outperforms competitors on strong trading day

Revvity Inc. (RVTY) stock advanced 1.86% to $117.88 on Wednesday, outperforming the S&P 500 Index and the Dow Jones Industrial Average. The stock closed just 0.35% shy of its 52-week high of $118.30. This performance occurred on a mixed trading day for the broader …

Revvity Inc (RVTY) Earnings Forecast: Future EPS & Revenue Growth Estimates

Revvity : Quarterly Report for Quarter Ending July 5, 2026 (Form 10-Q)

Revvity, Inc. released its quarterly report for the quarter ending July 5, 2026, detailing a 1% increase in overall revenue to $729.7 million compared to the prior year. This growth was primarily driven by a 5% increase in the Diagnostics segment, while the Life …

Revvity (RVTY) grows Q2 revenue, boosts cash and plans China diagnostics exit

Revvity (RVTY) reported a 1% increase in Q2 2026 revenue to $729.7 million, with Diagnostics growth offsetting a decline in Life Sciences. The company's gross margin improved to 57.1%, and operating cash flow from continuing operations reached $317.8 million for the first half of …

Revvity to Present at Upcoming Investor Conferences

WALTHAM, Mass., August 11, 2026--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: Wells Fargo 21st Annual Healthcare Conference Wednesday, September 9, 2026 8:45 a.m. ET - Prahlad Singh, president and chief executive officer Morgan Stanley 24th Annual …

Revvity (RVTY) Lifted Its Outlook, Is The Stock Fully Priced?

Revvity (RVTY) recently released its Q2 2026 results and declared a dividend, leading to a lifted outlook. The stock has seen positive short-term momentum, but its valuation is split, with a fair value estimate suggesting it's undervalued at $121.07, while its P/E ratio of …

Revvity Inc. stock underperforms Monday when compared to competitors despite daily gains

Revvity Inc. (RVTY) stock rose by 1.19% on Monday, closing at $116.02, marking its second consecutive day of gains. Despite this individual gain, the stock underperformed compared to the broader market, as the S&P 500 Index (SPX) fell 0.06% and the Dow Jones Industrial …

Revvity Launches SuperFlex Prenatal Screening System for Preeclampsia

Revvity has introduced the SuperFlex prenatal screening system, a compact immunoassay instrument designed for small to mid-sized laboratories and clinics to offer preeclampsia testing and biochemical screening. This CE-IVDR certified system aims to lower financial and operational barriers to in-house prenatal screening, providing access …

Revvity, Inc. (RVTY) Stock Forecasts

Morningstar analyst Julie Utterback published a report on Revvity, Inc. (RVTY), a global life sciences and diagnostics company. The report, titled "Revvity Earnings: Strong but Dressed-Up Quarter Boosts 2026 Outlook," was released on August 4, 2026. Revvity operates in life sciences and signals software …

Revvity Launches SuperFlex Prenatal Screening System, Expanding Access to Preeclampsia Testing

Revvity's new maternal and fetal biochemistry testing platform Designed for accessibility, simplicity, and flexibility Purpose-built for small to mid-sized labs and clinics to enable this capability in-house for the first time WALTHAM, Mass., August 10, 2026--(BUSINESS WIRE)--Revvity, Inc. today announced the launch of the …

Will Raised 2026 Revenue Guidance and Diagnostics Strength Change Revvity's (RVTY) Narrative

Revvity, Inc. recently reported strong Q2 2026 results, including increased revenue guidance and robust Diagnostics performance, leading to a reaffirmed quarterly dividend. Management attributes this positive outlook to improved pharma and biotech demand and a strategic exit from its China immunodiagnostics business. This shift …

Revvity Q2 Earnings Call Highlights

Revvity (RVTY) reported strong second-quarter results, exceeding expectations and raising its full-year outlook due to robust diagnostics performance and increasing demand from pharmaceutical and biotech sectors, particularly in AI-enabled drug discovery. The company saw pro forma organic revenue growth of 3% and adjusted earnings …

Revvity, Inc. (0KHE) Q3 2022 Earnings Report - Results, Call & Slides

Revvity, Inc. (0KHE) has released its Q3 2022 earnings report, showing an actual EPS of $1.51, which beat the consensus EPS of $1.44. However, the company missed revenue expectations, reporting $711.80 million against an expected $1.02 billion, a 38.99% year-over-year decrease. The earnings call …

Arrowstreet Capital Limited Partnership Sells 328,169 Shares of Revvity Inc. $RVTY

Does Revvity’s Q2 Beat, Higher Guidance and China Exit Alter the Bull Case for RVTY?

Revvity, Inc. reported past second-quarter 2026 results with sales of US$729.69 million, net income of US$51.82 million and diluted EPS from continuing operations of US$0.48, while also reaffirming a regular US$0.07 per-share quarterly dividend and issuing full-year 2026 revenue guidance of US$2.83 billion to …

Revvity Inc. Lifts Guidance After Strong Earnings

Revvity Inc. reported strong Q2 earnings, exceeding revenue and EPS guidance, leading to raised full-year targets. The Diagnostics segment and high-content screening orders were key growth drivers, while software revenue experienced volatility. The company also demonstrated strong cash flow, deleveraging progress, and an accelerated …

Why Revvity (RVTY) Stock Is Up Today

Shares of Revvity (NYSE:RVTY) jumped 3.1% after the life sciences company reported strong second-quarter 2026 results that exceeded Wall Street expectations and raised its full-year guidance. The company announced adjusted EPS of $1.41 on revenue of $729.68 million, driven by 11% organic growth in …

Stifel raises Revvity stock price target to $110 on earnings beat

Stifel increased its price target for Revvity Inc (NYSE:RVTY) shares to $110 from $100, maintaining a Hold rating after the company reported strong Q2 2026 earnings that exceeded expectations. The beat was partly due to tariff refunds and tax savings, but also organic growth …

Barclays Adjusts Price Target on Revvity to $115 From $105, Maintains Equalweight Rating

Barclays has increased its price target for Revvity (RVTY) shares to $115 from $105, while maintaining an Equalweight rating on the stock. This adjustment reflects an updated outlook from the analyst firm. The article also briefly mentions other analysts like Bernstein, Evercore ISI, and …

Revvity posts solid Q2 2026 earnings growth

Evercore ISI Adjusts Price Target on Revvity to $126 From $125, Maintains Outperform Rating

Evercore ISI has increased its price target for Revvity (RVTY) to $126 from $125, while reaffirming its "Outperform" rating on the stock. This adjustment reflects continued positive sentiment from the analyst firm regarding Revvity's financial prospects and market position. The update follows recent financial …

Revvity Inc reports results for the quarter ended June 30 - Earnings Summary

Revvity Inc has released its earnings summary for the quarter that ended on June 30. The article, provided by Refinitiv and distributed through TradingView, is an earnings report. Full access to the complete article and other news sources is available through a TradingView subscription.

Revvity (RVTY) Stock Premium Faces Pressure From Thin Margins

Revvity (RVTY) stock experienced a 3% dip despite exceeding Q2 earnings expectations, raising concerns about its high P/E ratio of 52.4x and recent squeeze in net profit margin to 8.2%. The article explores both the bullish arguments, such as organic growth in diagnostics and …

Amundi Sells 32,858 Shares of Revvity Inc. $RVTY

No-Moat Revvity Sees Solid First-Half Performance With Momentum Likely to Continue

Revvity, formerly PerkinElmer, has demonstrated solid first-half performance in 2026, with strong earnings boosting its outlook. The company, which rebranded after divesting its applied, food, and enterprise services business, now focuses on diagnostics and life sciences. This positive momentum is expected to continue, driven …

Revvity raises annual profit, revenue forecasts on strong diagnostics demand

Medical equipment maker Revvity has increased its annual profit and revenue forecasts after exceeding Wall Street expectations for the second quarter. This improvement is attributed to stronger demand for its drug-development tools and diagnostic testing products, with AI-related work contributing to incremental demand. Despite …

RVTY Q2 Earnings Beat Estimates on Diagnostics Strength, '26 View Up

Revvity, Inc. (RVTY) reported strong second-quarter 2026 results, with adjusted EPS of $1.41 and revenues of $729.7 million, both surpassing analyst estimates, driven by strength in its Diagnostics segment. The company also raised its full-year 2026 pro forma outlook for revenues and adjusted EPS. …

Revvity Inc (RVTY) (Q2 2026) Earnings Call Highlights: Strong Diagnostics Growth and Raised ...

This article first appeared on GuruFocus. Total Revenue: $711 million in Q2 2026, with pro forma organic growth of 3%. Adjusted EPS: $1.41, above the high end of guidance. Adjusted Operating Margin: 29.3% in the quarter, above the 27% outlook. Free Cash Flow: $184 …

Revvity outlines 2026 organic growth of 4% to 5% and adjusted EPS of $5.30 to $5.40, driven by diagnostics momentum and AI-linked demand

Earnings Call Insights: Revvity (RVTY) Q2 2026 MANAGEMENT VIEW * "I'm pleased to report that Revvity delivered strong results in the second quarter with pro forma organic growth of 3%, resulting in total revenue being above the high end of our expectations," said (CEO, …

Earnings call transcript: Revvity beats Q2 2026 estimates, but shares fall premarket

Revvity (RVTY) announced strong Q2 2026 results, exceeding adjusted EPS and revenue estimates, driven by organic growth, wider margins, and increased demand linked to AI. Despite the beat and raised full-year guidance for organic growth, operating margin, and EPS, the company's shares fell in …